H.Res. 1285 · 119th Congress

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Stage
In committee
Sponsor
Diana DeGette
Introduced
2026-05-14
Latest action
2026-05-14 · Submitted in House

Action history

  1. 2026-05-14Submitted in House
  2. 2026-05-14Referred to the House Committee on Energy and Commerce.
  3. 2026-05-14Submitted in House
  4. 2026-05-14Submitted in House
  5. 2026-05-14Referred to the House Committee on Energy and Commerce.
  6. 2026-05-14Submitted in House
  7. 2026-05-14Submitted in House
  8. 2026-05-14Referred to the House Committee on Energy and Commerce.